Study on Genetically Affected Sporadic Thoracic Aortic Aneurysm and Dissection

Aneurysm of Aorta, Thoracic Clinical Trial

— GenSTAND  

Official title:

Study on Genetically Affected Sporadic Thoracic Aortic Aneurysm and Dissection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02852603
• Other study ID #: 2016LMC-2
• Status: Completed
• Start date: August 2014
• Est. completion date: January 2020

Study information

• Verified date: April 2021
• Source: Wuhan Asia Heart Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Mortality of thoracic aortic aneurysm and dissection (TAAD) remains high because of the huge blood lost from the aorta. Questions about the potentially genetic effects on sporadic TAAD are raised by researchers to explore the possible mechanisms leading to sporadic TAAD and to establish new clinical approaches to prevent TAAD-caused adverse clinical outcomes. This study is intended to collect the gene information in sporadic TAAD patients and to explore the relationship between genetic variation and the incidence of sporadic TAAD for further study.

Description:

Thoracic aortic dissection (TAD) is a critical clinical condition partly due to the rupture of aortic aneurysm. Mostly, surgical treatment can reduce the symptoms and extend life span of patients with thoracic aortic aneurysm and dissection (TAAD). However, mortality of TAAD remains high because of the huge blood lost from the aorta. Sporadic TAAD was considered to be a server consequence of hypertension, though most patients with hypertension won't have TAAD as their final outcomes. Previous studies have revealed the associations between genetic abnormalities and familial TAAD, and genetic tests have applied to assist the diagnosis of certain TAAD. Therefore, the potentially genetic effects on sporadic TAAD are explored by researchers to understand the possible mechanisms leading to sporadic TAAD and to establish new clinical approaches to prevent TAAD-caused adverse clinical outcomes. This study is intended to collect the gene information in sporadic TAAD patients and to explore the relationship between genetic variation and the incidence of sporadic TAAD for further study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 450
• Est. completion date: January 2020
• Est. primary completion date: January 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with thoracic aortic aneurysm and dissection not due to trauma

Exclusion Criteria:

• Inability of the patient, parent or guardian to give consent

• Unwillingness to provide a blood specimen or participate in the study

Related Conditions & MeSH terms

• Aneurysm
• Aneurysm of Aorta, Thoracic
• Aneurysm, Dissecting
• Aortic Aneurysm
• Aortic Aneurysm, Thoracic
• Dissection of Aorta, Thoracic

Locations

Country	Name	City	State
China	Wuhan Asia Heart Hospital	Wuhan	Hubei

Sponsors (2)

Lead Sponsor	Collaborator
Wuhan Asia Heart Hospital	Fu Wai Hospital, Beijing, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Numbers of patients having thoracic aortic aneurysm and/or dissection are recorded. Diagnosis are confirmed by imaging analysis (CTA and/or Ultrasound) or by doctors during the operations.	Arterial dissection actually happened	6 months